Stojek Magdalena, Jabłońska Anna, Adrych Krystian
Department of Gastroenterology and Hepatology, Medical University of Gdansk, ul. Smoluchowskiego 17, 80-210 Gdańsk, Poland.
J Clin Med. 2021 Sep 8;10(18):4055. doi: 10.3390/jcm10184055.
The exact pathogenesis of inflammatory bowel disease (IBD) is still not completely understood. It is hypothesized that a genetic predisposition leads to an exaggerated immune response to an environmental trigger, leading to uncontrolled inflammation. As there is no known causative treatment, current management strategies for inflammatory bowel disease focus on correcting the excessive immune response to environmental (including microbial) triggers. In recent years, there has been growing interest in new avenues of treatment, including targeting the microbial environment itself. Fecal microbiota transplantation (FMT) is a novel treatment modality showing promising results in early studies. The article discusses the rationale for the use of FMT in inflammatory bowel disease and the yet-unresolved questions surrounding its optimal use in practice.
炎症性肠病（IBD）的确切发病机制仍未完全明确。据推测，遗传易感性会导致对环境触发因素产生过度免疫反应，进而引发失控的炎症。由于尚无已知的病因治疗方法，目前炎症性肠病的管理策略侧重于纠正对环境（包括微生物）触发因素的过度免疫反应。近年来，人们对新的治疗途径越来越感兴趣，包括针对微生物环境本身。粪便微生物群移植（FMT）是一种新型治疗方式，在早期研究中显示出有前景的结果。本文讨论了在炎症性肠病中使用FMT的理论依据以及围绕其在实际应用中的最佳使用尚未解决的问题。
